The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Parvus Asset Management is building a stake in Novo Nordisk and hopes to influence its choice of a new CEO. Novo Nordisk ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Advert Previous studies linked the drug to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy ...

Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Investing.com -- Parvus Asset Management, a London-based activist hedge fund, is acquiring a stake in Danish pharmaceutical company Novo Nordisk (NYSE: NVO ), according to The Financial Times. The ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...